These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 12379628)

  • 1. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.
    Rau R
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii70-3. PubMed ID: 12379628
    [No Abstract]   [Full Text] [Related]  

  • 2. Adalimumab for rheumatoid arthritis.
    Voulgari PV; Drosos AA
    Expert Opin Biol Ther; 2006 Dec; 6(12):1349-60. PubMed ID: 17223742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].
    Hirohata S
    Nihon Rinsho; 2007 Jul; 65(7):1202-8. PubMed ID: 17642233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab therapy in rheumatoid arthritis.
    Keystone E; Haraoui B
    Rheum Dis Clin North Am; 2004 May; 30(2):349-64, vii. PubMed ID: 15172045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
    Bongartz T; Sutton AJ; Sweeting MJ; Buchan I; Matteson EL; Montori V
    JAMA; 2006 May; 295(19):2275-85. PubMed ID: 16705109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody.
    Kempeni J
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i44-5. PubMed ID: 11053087
    [No Abstract]   [Full Text] [Related]  

  • 8. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis.
    Mease PJ
    Expert Opin Biol Ther; 2005 Nov; 5(11):1491-504. PubMed ID: 16255652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
    Gaudin P
    Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.
    van de Putte LB; Rau R; Breedveld FC; Kalden JR; Malaise MG; van Riel PL; Schattenkirchner M; Emery P; Burmester GR; Zeidler H; Moutsopoulos HM; Beck K; Kupper H
    Ann Rheum Dis; 2003 Dec; 62(12):1168-77. PubMed ID: 14644854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA; Agudo M
    Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
    [No Abstract]   [Full Text] [Related]  

  • 12. Adalimumab for rheumatoid arthritis?
    Ebell M; Kripke C
    Am Fam Physician; 2006 Feb; 73(3):435-6. PubMed ID: 16479667
    [No Abstract]   [Full Text] [Related]  

  • 13. New antibody approved for treatment of rheumatoid arthritis.
    Piascik P
    J Am Pharm Assoc (Wash); 2003; 43(2):327-8. PubMed ID: 12688444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice.
    Kievit W; Fransen J; Oerlemans AJ; Kuper HH; van der Laar MA; de Rooij DJ; De Gendt CM; Ronday KH; Jansen TL; van Oijen PC; Brus HL; Adang EM; van Riel PL
    Ann Rheum Dis; 2007 Nov; 66(11):1473-8. PubMed ID: 17426065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which TNF inhibitor for rheumatoid arthritis?
    Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356
    [No Abstract]   [Full Text] [Related]  

  • 17. New drugs for rheumatoid arthritis.
    Messori A; Santarlasci B; Vaiani M
    N Engl J Med; 2004 Aug; 351(9):937-8. PubMed ID: 15329436
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of type 1 diabetes mellitus in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor alpha.
    Richez C; Blanco P; Gin H; Schaeverbeke T
    Clin Exp Rheumatol; 2006; 24(5):607. PubMed ID: 17181936
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis.
    Hochberg MC; Tracy JK; Hawkins-Holt M; Flores RH
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii13-6. PubMed ID: 14532140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of anti-tumor necrosis factor agents.
    Wong JB
    Clin Exp Rheumatol; 2004; 22(5 Suppl 35):S65-70. PubMed ID: 15552517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.